Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06995729

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it.

This study is seeking participants who:

* Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms

All participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). The dose of the study medicine that each participant receives will depend on how much the participant weighs.

The study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine.

Participants will take part in this study for up to 10 weeks. During this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Treatment of Migraine Brain Diseases Central Nervous System Diseases Headache Disorders Headache Disorders, Primary Migraine Disorders Nervous System Diseases

Age range

6 year–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Arkansas Children's Hospital, Little Rock, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants aged 6 years to less than 12 years.
  • Documented medical history of migraine with or without aura for at least 6 months before the Screening Visit.
  • Weight >15 kg at the Screening Visit

Exclusion criteria

  • Evidence or history of clinically significant disease.
  • Continuous migraine (defined as an unrelenting headache) within 1 month prior to Screening Visit.
  • Atypical migraine types, complications of a migraine, or a confounding and clinically significant pain syndrome.
  • Conditions that may affect the administration or absorption of the nasal product
  • Any psychiatric condition that is uncontrolled and/or untreated, including:
  • Clinically significant depression (Promis Parent Proxy SF 2.0 Depressive Scale T score ≥70)
  • Suicidal ideation and behaviour (C-SSRS: any "yes" to items 2 to 5 or any "yes" to suicide behaviours)
  • Serum Total bilirubin >1.5 × ULN (Upper Limit of Normal), AST (Aspartate Transferase) or ALT (Alanine Transaminase) >2 × ULN
  • Abnormal ECG (Electrocardiogram) at screening visit

Treatment and study plan

Zavegepant

Drug

Zavegepant 5 mg or 10 mg (dose is weight-dependent)

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours

    Cmax is defined as the maximum observed plasma concentration of zavegepant after administration of a single dose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours

    Tmax is defined as the time to reach maximum observed plasma concentration

  3. Area Under the Curve From Time Zero to infinity.

    Time frame: Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours

    AUC (0 - inf) is defined as area under the concentration-time curve from time 0 to infinity.

Secondary outcomes

  1. Number of Participants with All-Causality Treatment-emergent Adverse Events (TEAEs)

    Time frame: TEAE is reported from informed consent up to 28 days after administration of study drug.

    An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.

  2. Number of participants with clinically significant abnormal vital signs

    Time frame: Assessed from screening up to 6 days after administration of study drug

    Vital sign measurements include temperature, respiratory rate, pulse rate, and blood pressure.

  3. Number of participants with clinically significant abnormal laboratory findings

    Time frame: Assessed from screening up to 6 days after administration of study drug

    Laboratory assessment includes hematology, chemistry and urinalysis. Clinical significance of laboratory abnormalities was judged by investigator.

  4. Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: Assessed from screening up to 6 days after administration of study drug

    The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. The C-SSRS assessment MUST be performed by an adequately trained, certified, and delegated rater. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

Study contacts

Contact information is provided by the study sponsor or research team.

Pfizer CT.gov Call Center

CONTACT

[email protected]

1-800-718-1021

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A PHASE 1, MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
May 29, 2025
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.